HC Wainwright Has Positive Estimate for GLUE FY2026 Earnings

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) – Investment analysts at HC Wainwright raised their FY2026 EPS estimates for Monte Rosa Therapeutics in a research note issued to investors on Friday, November 6th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($1.30) per share for the year, up from their prior estimate of ($1.81). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Monte Rosa Therapeutics’ current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Monte Rosa Therapeutics’ Q4 2026 earnings at ($0.49) EPS, Q2 2027 earnings at ($0.55) EPS and FY2027 earnings at ($2.23) EPS.

GLUE has been the topic of a number of other research reports. Wells Fargo & Company lowered their price objective on Monte Rosa Therapeutics from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday. Benchmark restated a “buy” rating on shares of Monte Rosa Therapeutics in a report on Monday, October 5th. TD Cowen upgraded Monte Rosa Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. JPMorgan Chase & Co. decreased their target price on Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded Monte Rosa Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $26.44.

Monte Rosa Therapeutics Price Performance

Shares of NASDAQ:GLUE opened at $10.58 on Tuesday. Monte Rosa Therapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $25.77. The business has a 50-day moving average of $11.65 and a two-hundred day moving average of $17.02. The stock has a market capitalization of $902.58 million, a P/E ratio of -7.56 and a beta of 1.40.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, November 5th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.24. Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%. The company had revenue of $54.37 million for the quarter, compared to analyst estimates of $33.87 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GLUE. Allworth Financial LP bought a new stake in Monte Rosa Therapeutics during the second quarter valued at about $30,000. Sterling Capital Management LLC increased its stake in shares of Monte Rosa Therapeutics by 842.3% in the third quarter. Sterling Capital Management LLC now owns 2,450 shares of the company’s stock worth $29,000 after purchasing an additional 2,190 shares during the period. State of Alaska Department of Revenue bought a new position in shares of Monte Rosa Therapeutics in the third quarter worth about $48,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Monte Rosa Therapeutics in the third quarter worth about $52,000. Finally, E Fund Management Co. Ltd. bought a new position in shares of Monte Rosa Therapeutics in the second quarter worth about $200,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments.

The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.